The National Health Surveillance Agency (Anvisa) strengthened its oversight actions by prohibiting the commercialization of irregular dietary supplements and a counterfeit medication, reaffirming its commitment to the safety and quality of products available in the Brazilian pharmaceutical market.
The measure represents part of the agency's continuous operations to protect the population against products that do not meet required regulatory standards. The irregular supplements identified lacked proper registration with Anvisa, a mandatory condition for any product of this nature to be legally marketed in the country.
Beyond registration irregularities, the agency also identified and prohibited the sale of a counterfeit medication, whose manufacturer and origin did not meet the authenticity and safety criteria established by Brazilian health legislation. The commercialization of counterfeit medications represents a significant risk to public health, as it compromises the efficacy and safety expected from treatments.
These prohibitions demonstrate the importance of continuous oversight of pharmaceutical products and supplements. Anvisa advises consumers to verify that products are registered with the agency before purchasing them, information available on the institution's website. Irregular or counterfeit products should be reported to the regulatory body.
The action reinforces that only regularized products, which have undergone rigorous safety and efficacy evaluation, can be offered to the market. Consumers should be vigilant and purchase supplements and medications only from authorized establishments with proven origin.
Anvisa maintains its inspection operations and intends to continue intensifying actions against irregular products that could compromise the health of the Brazilian population.
